Docetaxel in the treatment of hormone-resistant prostate cancer
Docetaxel is the most effective chemical agent used in the treatment of hormone-resistant prostate cancer (HRPC). Three different docetaxel-based combinations were tested. The study included 30 patients with HRPC: 10 patients received chemotherapy as intravenous docetaxel, 75 mg/m2 once every 21 day...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-02-01
|
| Series: | Onkourologiâ |
| Online Access: | https://oncourology.abvpress.ru/oncur/article/view/1087 |